CJC-1295 + Ipamorelin
$39.00
For research use only. Not for human or veterinary use.
CJC-1295 + Ipamorelin is a research blend of two growth hormone secretagogues that act on different receptors, supplied together in a single lyophilized vial.
CJC-1295 is a modified GRF(1-29) analog carrying amino acid substitutions that increase its resistance to enzymatic degradation; it binds the GHRH receptor on pituitary somatotroph cells. Ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a) and acts through a separate signaling pathway. The two are studied together to compare receptor-specific signaling against the combined preparation.
Researchers study this blend in:
- GHRH receptor and GHS-R1a binding assays
- Somatotroph cell culture models
- Receptor selectivity studies
- Comparative studies of single-agonist versus combined preparations
- Peptide stability and formulation research
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For research use only; not for human or veterinary use.
WHAT'S INSIDE
Two Sequences, One Vial
Each component acts on a different receptor of the same cell type, which is what makes the combined preparation worth studying against the single ones.
| CJC-1295 (no DAC) | Ipamorelin |
|---|---|
| A modified GRF(1-29) analog, 3,367.9 g/mol, 29 amino acids. Binds the GHRH receptor on pituitary somatotroph cells; the substitutions increase resistance to enzymatic degradation. | A selective agonist of the ghrelin receptor (GHS-R1a), 711.9 g/mol, 5 amino acids. Acts through a separate signaling pathway. |
Characterization above refers to published in vitro and animal-model literature. No human outcome is claimed or implied.
MECHANISM
What Is Studied
A blend of two secretagogue sequences that act on different receptors, supplied in a single lyophilized vial. Each engages a separate signaling pathway on pituitary somatotroph cells.
| GHRH Receptor | GHS-R1a Receptor | Comparative Studies |
|---|---|---|
| A modified GRF(1-29) analog binds the GHRH receptor; amino acid substitutions increase its resistance to enzymatic degradation. | A selective ghrelin receptor agonist acts through a separate pathway on the same cell type. | Receptor selectivity assays compare single-agonist preparations against the combined one. |
Characterization above refers to published in vitro and animal-model literature. No human outcome is claimed or implied.
DISCLAIMER
This product is exclusively for laboratory research. Not approved for human or veterinary use. All products sold by Ikon Peptides are intended exclusively for in-vitro laboratory research. Not approved for human consumption or veterinary use.
PHYSICAL PROPERTIES
Key specifications for handling and storage in laboratory settings:
| Composition | CJC-1295 (no DAC) + Ipamorelin blend |
| CJC-1295 MW | 3,367.9 g/mol — 29 amino acids (Mod GRF 1-29) |
| Ipamorelin MW | 711.9 g/mol — 5 amino acids |
| Form | White lyophilized powder blend |
| Solubility | Water-soluble |
| Storage | Refrigerated 36-46 F (2-8 C). Protect from light. Avoid freeze-thaw cycles. |
| Stability | 24 months lyophilized. |
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Related products
